Latest Cell And Gene Therapy News

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.

Bluechiip Limited advances its strategic repositioning with a new licensing agreement valued up to USD 750,000 alongside ongoing efforts to lift its trading suspension and grow sales.